Form 4: Strata Critical Medical Officer Granted 51,353 RSUs

Scott M. Wunsch, CEO of Trinity Air Medical and an officer of Strata Critical Medical, Inc., was granted 51,353 Restricted Stock Units (RSUs) on February 24, 2026.

Summary

• Scott M. Wunsch, an officer of Strata Critical Medical, Inc. and CEO of Trinity Air Medical, received a grant of 51,353 Restricted Stock Units (RSUs).
• The transaction date for this grant was February 24, 2026.
• The RSUs will be settled in shares of the Issuer's common stock upon vesting.
• Vesting schedule dictates that 6.25% of the RSUs will vest every 3 months after March 8, 2026.
• Any remaining unvested RSUs are scheduled to vest on March 8, 2030, contingent on Mr. Wunsch's continued service to the Issuer.
• Following this transaction, Mr. Wunsch directly beneficially owns 573,438 shares of Class A common stock.
• Additionally, Mr. Wunsch indirectly beneficially owns 382,987 shares of Class A common stock through a limited liability company where he is the sole member.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, primarily due to the alignment of executive incentives with long-term shareholder value, which is a standard and healthy corporate governance practice.

Positives

• The grant of Restricted Stock Units (RSUs) aligns the interests of Scott M. Wunsch, a key officer, with those of the shareholders, as the value of his compensation is tied to the company's stock performance.
• The long-term vesting schedule, extending to March 8, 2030, incentivizes Mr. Wunsch's continued service and commitment to Strata Critical Medical, Inc.

Risks

• The vesting of the Restricted Stock Units is subject to the Reporting Person's continued service to the Issuer, meaning a departure could result in forfeiture of unvested shares.

Future Outlook

The RSU grant with a vesting schedule extending to March 8, 2030, indicates a long-term commitment from Scott M. Wunsch to Strata Critical Medical, Inc., aligning his future financial incentives with the company's performance and growth over several years.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units (RSUs) to an executive is a standard practice in the biotechnology and medical technology sectors. This form of equity compensation is widely used to attract, retain, and motivate key personnel by linking their financial success directly to the long-term performance of the company's stock. It reflects a common strategy to ensure management's interests are aligned with shareholder value creation.

Stakeholder Impact

• Shareholders: The RSU grant aligns management's long-term interests with shareholder value, potentially leading to more focused efforts on stock appreciation.
• Employees: The compensation structure for a key officer may set a precedent or reflect the company's overall approach to executive incentives.

Next Steps

• The RSUs will begin vesting quarterly at 6.25% after March 8, 2026.
• Any remaining unvested RSUs will vest on March 8, 2030, subject to continued service.

Key Dates

Keywords

Strata Critical Medical, SRTA, Restricted Stock Units, RSU grant, insider transaction, executive compensation, Scott M. Wunsch, Form 4, equity compensation, vesting schedule